DelfaGLP-1 Atlas

Lead sponsor

University of Miami

6 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

6

Trials led

2

Active

302

Total enrollment

1

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 4
5
Not applicable
1

Trials by status

Recruiting
1
Active, not recruiting
1
Completed
3
Withdrawn
1

Trials led

Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 DiabetesBMI ≥27Ph 4Completed100
Semaglutide vs Dulaglutide on Epicardial Adipose TissueBMI ≥27not applicableCompleted80
LEAFBMI ≥27Ph 4Active, not recruiting60
Liraglutide Effects on Epicardial Fat Inflammatory GenesBMI ≥27Ph 4Completed38
Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) PatientsBMI ≥27Ph 4Recruiting24
Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial FatBMI ≥27Ph 4Withdrawnnot disclosed